Transcriptome-based RNA sequencing

Question 1

With xT do we also transcribe the RNA?

Answer 1

Yes

Question 2

Through which mechanism?

Answer 2

Transcriptome based sequencing

Question 3

What metrics do we look for?

Answer 3

• Genes
• Depth of coverage
• Alterations reported
• Specimen requirements
• Tumor content

Question 4

Gene count?

Answer 4

20,000

Question 5

Depth of coverage?

Answer 5

50 million reads per sample

Question 6

Alterations reported?

Answer 6

fusions rearrangements

Question 7

specimen requirements?

Answer 7

• Nothing additional is required beyond what is submitted for tumor.
• RNA seq is only run if enough tumor is available following the DNA sequencing.

Question 8

Why do we look at the RNA?

Answer 8

To better identify some of the translocations and if that fusion is truly “functional” .

Question 9

What is bated fusion?

Answer 9

looks for common and known gene fusions.

Question 10

what is transcriptome- based RNA sequencing?

Answer 10

looks across the RNA transcriptome for both common and novel gene fusions.

Question 11

Transcriptome-based sequencing is going to provide the physician with more clinically relevant information. True or false?

Answer 11

True

Question 12

Tempus Transcriptome-Based RNA sequencing facts. What are they?

Answer 12

See the following cards:

Question 13

1.)

Answer 13

clinically validated for unbiased gene fusion calling

Question 14

2.)

Answer 14

comprehensively captures all gene fusions.

Question 15

3.)

Answer 15

some elements of RNA seq. used for research-only purposes

Question 16

4.)

Answer 16

Tempus has the world’s largest RNA seq. database!

Question 17

How can the test analyze proteins?

Answer 17

through IHC

Question 18

There are two IHC add on tests. What are they?

Answer 18

1. ) MMR IHC

2. ) PD-L1IHC

Question 19

if PD-L1IHC is ordered, what other options can they choose?

Answer 19

• The clones

Question 20

What is the default “clone” on the testing option section

Answer 20

22c3

Question 21

If the clinician orders PD-L1, what additional requirements are needed for this test to be run?

Answer 21

3 additional FFPE unstained slides with 20% tumor content.

Question 22

What about for MMR?

Answer 22

6 additional FFPE unstained slides with 20% tumor content.

Question 23

What does immunohistochemistry examine?

Answer 23

protein expression

Question 24

Why would a doctor order the additional PD-L1 and MMR IHC options?

Answer 24

to help predict patient response to checkpoint inhibitors.

Question 25

What does a T cell try to recognize on a tumor cell in order to destroy it?

Answer 25

An antigen

Question 26

What are PD-1 and PD-L1 inhibitors again?

Answer 26

-Checkpoint inhibitor drugs, line of immunotherapy.

Question 27

What do the checkpoint inhibitors do?

Answer 27

Block the tumors protein that’s attaching to the T-Cell, inhibit the tumor growth, and stop replication and spread of cancer.